Minerva Neurosciences, Inc. (NERV): Nasdaq/NYSE listing notice — Minerva Neurosciences receives Nasdaq notice for MVLS non-compliance; has until May 30, 2023

Minerva Neurosciences, Inc.

Nasdaq notified Minerva on Dec 1, 2022 that MVLS fell below $35M for 30 consecutive business days.
Company has until May 30, 2023 to regain compliance by closing at $35M for ten consecutive business days.
No immediate delisting; stock continues trading on Nasdaq Capital Market under symbol NERV.
If not compliant by May 30, 2023, Nasdaq may delist; company may seek extension or appeal.
Company is evaluating options to regain compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Minerva Neurosciences, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

December 1, 2022, Minerva Neurosciences, Inc. (the “Company”) received notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the Company’s minimum Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided an initial period of 180 calendar days, or until May 30, 2023, to regain compliance. The letter states that the Nasdaq

View on SEC.gov

Browse all listing & compliance notices →

Minerva Neurosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-297518

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.